Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis
Abstract
1. Introduction
2. Experimental Section
2.1. Data Sources
2.2. Study Cohort and Identification of Endocrine Therapy Exposure
2.3. Outcomes and Measures
2.4. Covariates
2.5. Statistical Analysis
2.6. Stratification/Sensitivity Analysis
3. Results
3.1. AI Use and Risk of Any Arthritis
3.2. AI Use and Risk of Carpal Tunnel Syndrome
3.3. Sensitivity/Stratification Analyses
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. J. Int. Du Cancer 2015, 136, E359–E386. [Google Scholar] [CrossRef]
- National Comprehensive Cancer Network. Breast Cancer. Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed on 16 April 2018).
- Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.; Sahmoud, T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002, 359, 2131–2139. [Google Scholar]
- Mouridsen, H.; Gershanovich, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H.P.; Janicke, F.; et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001, 19, 2596–2606. [Google Scholar] [CrossRef] [PubMed]
- Niravath, P. Aromatase inhibitor-induced arthralgia: A review. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2013, 24, 1443–1449. [Google Scholar] [CrossRef] [PubMed]
- Beckwee, D.; Leysen, L.; Meuwis, K.; Adriaenssens, N. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: A systematic review and meta-analysis. Supportive Care Cancer Off. J. Multinatl. Assoc. Supportive Care Cancer 2017, 25, 1673–1686. [Google Scholar] [CrossRef] [PubMed]
- Mao, J.J.; Stricker, C.; Bruner, D.; Xie, S.; Bowman, M.A.; Farrar, J.T.; Greene, B.T.; DeMichele, A. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009, 115, 3631–3639. [Google Scholar] [CrossRef]
- Crew, K.D.; Greenlee, H.; Capodice, J.; Raptis, G.; Brafman, L.; Fuentes, D.; Sierra, A.; Hershman, D.L. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007, 25, 3877–3883. [Google Scholar] [CrossRef]
- Kanematsu, M.; Morimoto, M.; Honda, J.; Nagao, T.; Nakagawa, M.; Takahashi, M.; Tangoku, A.; Sasa, M. The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer 2011, 11, 436. [Google Scholar] [CrossRef]
- De Placido, S.; Gallo, C.; De Laurentiis, M.; Bisagni, G.; Arpino, G.; Sarobba, M.G.; Riccardi, F.; Russo, A.; Del Mastro, L.; Cogoni, A.A.; et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): A randomised, phase 3 trial. Lancet. Oncol. 2018, 19, 474–485. [Google Scholar] [CrossRef]
- Yagata, H.; Ohtsu, H.; Komoike, Y.; Saji, S.; Takei, H.; Nakamura, T.; Ohashi, Y.; Iwase, T.; Shimozuma, K. Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. Supportive Care Cancer Off. J. Multinatl. Assoc. Supportive Care Cancer 2016, 24, 683–689. [Google Scholar] [CrossRef]
- Egawa, C.; Hirokaga, K.; Takao, S.; Yamagami, K.; Miyashita, M.; Baba, M.; Ichii, S.; Konishi, M.; Kikawa, Y.; Minohata, J.; et al. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: A prospective multicenter cohort study of patient-reported outcomes. Int. J. Clin. Oncol. 2016, 21, 262–269. [Google Scholar] [CrossRef] [PubMed]
- Youlden, D.R.; Cramb, S.M.; Yip, C.H.; Baade, P.D. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol. Med. 2014, 11, 101–115. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Ma, B.B.; Hui, E.P.; Mok, T.S. Population-based differences in treatment outcome following anticancer drug therapies. Lancet. Oncol. 2010, 11, 75–84. [Google Scholar] [CrossRef]
- Guidelines for ATC Classification and DDD Assignment 2013; WHO Collaborating Centre for Drug Statistics Methodology: Oslo, Norway, 2012; Available online: https://www.whocc.no/filearchive/publications/1_2013guidelines.pdf (accessed on 16 April 2018).
- Mansell, J.; Monypenny, I.J.; Skene, A.I.; Abram, P.; Carpenter, R.; Gattuso, J.M.; Wilson, C.R.; Angerson, W.J.; Doughty, J.C. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res. Treat. 2009, 117, 91–98. [Google Scholar] [CrossRef] [PubMed]
- Klabunde CN, P.A.; Legler, J.M.; Warren, J.L. Development of a comorbidity index using physician claims data. J. Clin. Epidemiol. 2000, 53, 10. [Google Scholar] [CrossRef]
- Solomon, D.H.; Katz, J.N.; Bohn, R.; Mogun, H.; Avorn, J. Nonoccupational risk factors for carpal tunnel syndrome. J. Gen. Intern. Med. 1999, 14, 310–314. [Google Scholar] [CrossRef]
- Austin, P.C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 2011, 10, 150–161. [Google Scholar] [CrossRef]
- Mieog, J.S.; Morden, J.P.; Bliss, J.M.; Coombes, R.C.; Van de Velde, C.J. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: A retrospective analysis of the Intergroup Exemestane Study. Lancet. Oncol. 2012, 13, 420–432. [Google Scholar] [CrossRef]
- Sestak, I.; Sapunar, F.; Cuzick, J. Aromatase inhibitor-induced carpal tunnel syndrome: Results from the ATAC trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009, 27, 4961–4965. [Google Scholar] [CrossRef]
- Chronic Conditions Data Warehours. CCW Chronic Conditions. Available online: https://www.ccwdata.org/web/guest/condition-categories (accessed on 23 April 2018).
- Cecil, R.L.; Archer, B.H. Arthritis of the menopause: A study of fifty cases. J. Am. Med Assoc. 1925, 84, 75–79. [Google Scholar] [CrossRef]
- Geisler, J.; Helle, H.; Ekse, D.; Duong, N.K.; Evans, D.B.; Nordbo, Y.; Aas, T.; Lonning, P.E. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2008, 14, 6330–6335. [Google Scholar] [CrossRef]
- Smith, I.; Yardley, D.; Burris, H.; De Boer, R.; Amadori, D.; McIntyre, K.; Ejlertsen, B.; Gnant, M.; Jonat, W.; Pritchard, K.I.; et al. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 1041–1048. [Google Scholar] [CrossRef]
- Fernandes, R.; Mazzarello, S.; Hutton, B.; Shorr, R.; Majeed, H.; Ibrahim, M.F.; Jacobs, C.; Ong, M.; Clemons, M. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Supportive Care Cancer Off. J. Multinatl. Assoc. Supportive Care Cancer 2016, 24, 3633–3650. [Google Scholar] [CrossRef] [PubMed]
- Bair, M.J.; Robinson, R.L.; Katon, W.; Kroenke, K. Depression and pain comorbidity: A literature review. Arch. Intern. Med. 2003, 163, 2433–2445. [Google Scholar] [CrossRef] [PubMed]
- DiMatteo, M.R.; Lepper, H.S.; Croghan, T.W. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 2000, 160, 2101–2107. [Google Scholar] [CrossRef] [PubMed]
- David, G.; Kleinbaum, M.K. Survival Analysis. A Self-Learning Text, 3rd ed.; Springer: New York, NY, USA, 2012; pp. 127–131. Available online: https://epdf.pub/survival-analysis-a-self-learning-text-third-edition.html. (accessed on 18 February 2020).
- Hsieh, K.P.; Chen, L.C.; Cheung, K.L.; Yang, Y.H. Risks of nonadherence to hormone therapy in Asian women with breast cancer. Kaohsiung J. Med. Sci. 2015, 31, 328–334. [Google Scholar] [CrossRef]
Characteristics | Anastrozole (n = 1270, 3.9%) | Letrozole (n = 2573, 8.0%) | Exemestane (n = 233, 0.7%) | Tamoxifen (n = 27,979, 87.4%) | p Value |
---|---|---|---|---|---|
Mean age (SD) | 61.3 (10.8) | 60.3 (9.3) | 61.9 (10.5) | 51.4 (11.3) | <0001 |
Year of endocrine therapy initiation | |||||
2007–2010 | 932 (4.6) | 174 (0.9) | 1249 (6.2) | 17,825 (88.3) | <0001 |
2011–2012 | 338 (2.8) | 59 (0.5) | 1324 (11.1) | 10,154 (85.5) | |
History of treatment for breast cancer a | |||||
Primary tumor resection | 883 (69.5) | 1915 (74.4) | 95 (40.8) | 24,921 (89.1) | <0001 |
Radiation therapy | 171 (13.5) | 687 (26.7) | 29 (12.5) | 5386 (19.3) | <0001 |
Chemotherapy | |||||
No chemotherapy | 854 (67.2) | 1262 (49.1) | 148 (63.5) | 17,711 (63.3) | <0001 |
Non-taxane based | 228 (18.0) | 339 (13.2) | 31 (13.3) | 7237 (25.9) | |
Taxane based | 188 (14.8) | 972 (37.8) | 54 (23.2) | 3031 (10.8) | |
NCI index | |||||
0 | 853 (67.2) | 1697 (66.0) | 158 (67.8) | 22,573 (80.7) | <0001 |
1 | 243 (19.1) | 565 (22.0) | 45 (19.3) | 3753 (13.4) | |
≥2 | 174 (13.7) | 311 (12.1) | 30 (12.9) | 1653 (5.9) | |
Comorbidities/Medications b | |||||
Hypertension | 615 (48.4) | 1226 (47.7) | 106 (45.5) | 8529 (30.5) | <0001 |
Diabetes | 271 (21.3) | 529 (20.6) | 52 (22.3) | 2957 (10.6) | <0001 |
Dyslipidemia | 275 (21.7) | 599 (23.3) | 55 (23.6) | 3953 (14.1) | <0001 |
Affective disorders | 565 (44.5) | 1225 (47.6) | 104 (44.6) | 11,368 (40.6) | <0001 |
Chronic kidney disease | 24 (1.9) | 43 (1.7) | 4 (1.7) | 264 (0.9) | 0001 |
Liver cirrhosis | 22 (1.7) | 17 (0.7) | 4 (1.7) | 152 (0.5) | <0001 |
Wrist fracture | 10 (0.8) | 2 (0.9) | 13 (0.5) | 130 (0.5) | 34 |
Thyroxine | 27 (2.1) | 60 (2.3) | 2 (0.9) | 478 (1.7) | 06 |
Analgesic use | |||||
Opioids | 106 (8.4) | 206 (8.0) | 26 (11.2) | 1225 (4.4) | <0001 |
NSAIDs/acetaminophen | 1001 (78.8) | 2089 (81.2) | 174 (74.7) | 22,653 (81.0) | <0001 |
Type of treatment Hospitals | |||||
Located in capital areas | 859 (67.6) | 1389 (54.0) | 160 (68.7) | 15,565 (55.6) | <0001 |
Medical centers | 584 (46.0) | 909 (35.3) | 68 (29.2) | 11,852 (42.4) | <0001 |
Any Arthritis | Carpal Tunnel Syndrome | |||||
---|---|---|---|---|---|---|
Endocrine Therapy | Incidence, % | Unadjusted (HR, 95% CI) | Adjusted a (aHR, 95% CI) | Incidence, % | Unadjusted (HR, 95% CI) | Adjusteda (aHR, 95% CI) |
Tamoxifen | 8.2 | Referent | Referent | 0.8 | Referent | Referent |
AIs | 13.0 | 1.66 (1.51–1.82) | 1.21 (1.09–1.34) | 1.4 | 1.52 (1.13–2.03) | 1.68 (1.22–2.32) |
Tamoxifen | 8.2 | Referent | Referent | 0.8 | Referent | Referent |
Anastrozole | 12.0 | 1.54 (1.31–1.81) | 1.11 (0.94–1.31) | 1.3 | 1.52 (0.93–2.48) | 1.77 (1.07–2.93) |
Exemestane | 11.2 | 1.50 (1.02–2.21) | 1.10 (0.74–1.63) | 0.9 | 1.02 (0.25–4.10) | 1.30 (0.32–5.30) |
Letrozole | 13.6 | 1.73 (1.55–1.94) | 1.27 (1.12–1.44) | 1.4 | 1.56 (1.10–2.21) | 1.65 (1.13–2.42) |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chien, H.-C.; Kao Yang, Y.-H.; Kwoh, C.K.; Chalasani, P.; Wilson, D.L.; Lo-Ciganic, W.-H. Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis. J. Clin. Med. 2020, 9, 566. https://doi.org/10.3390/jcm9020566
Chien H-C, Kao Yang Y-H, Kwoh CK, Chalasani P, Wilson DL, Lo-Ciganic W-H. Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis. Journal of Clinical Medicine. 2020; 9(2):566. https://doi.org/10.3390/jcm9020566
Chicago/Turabian StyleChien, Hsu-Chih, Yea-Huei Kao Yang, C. Kent Kwoh, Pavani Chalasani, Debbie L. Wilson, and Wei-Hsuan Lo-Ciganic. 2020. "Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis" Journal of Clinical Medicine 9, no. 2: 566. https://doi.org/10.3390/jcm9020566
APA StyleChien, H.-C., Kao Yang, Y.-H., Kwoh, C. K., Chalasani, P., Wilson, D. L., & Lo-Ciganic, W.-H. (2020). Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis. Journal of Clinical Medicine, 9(2), 566. https://doi.org/10.3390/jcm9020566